drugset / Trial / NCT06540391
A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
A Phase 1b study to evaluate the safety and tolerability of MB097 given in combination with pembrolizumab in patients with melanoma who demonstrate primary resistance to anti-PD1 therapy.
Timeline
- Start
- 2024-08-28
- Primary completion
- 2025-12
- Completion
- 2027-08
Outcome
Met primary endpoint
release “announces that all primary and secondary objectives were met in its advanced melanoma (MELODY-1) Phase 1b trial.” microbiotica.com ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MB097 | Other / unclassified | — | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Background | Vancomycin | Other / unclassified | 125 mg | — |